Aton Pharma acquires Timoptic product line

Aton Pharma has acquired the marketing rights to the Timoptic product line from Merck & Co.  The Timoptic product line includes Timoptic (timolol maleate) ophthalmic solution, Timoptic Ocudose (timolol maleate) ophthalmic solution in a sterile ophthalmic unit dose dispenser, and Timoptic-XE (timolol maleate) ophthalmic gel forming solution.

Timoptic, Timoptic Ocudose, and Timoptic-XE are noncardioselective beta-blockers indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

For more information call (877) ATON-549 or visit www.atonrx.com.